title: Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
abstract: OBJECTIVE
  In multiple myeloma, many prognostic parameters have been proposed. However, all of these predict shorter survival. To identify patients with a longer life expectancy, we updated the data of patients treated in the IFM (Intergroupe Francophone du Myelome) 99-02 and 99-04 trials.
  
  
  METHODS
  A series of 520 patients was analyzed. Median follow-up was 90.5 months. To perform a comprehensive analysis of the major prognostic factors, we reanalyzed all patients for 1q gains [in addition to updating del(13), t(4;14), and del(17p) analyses].
  
  
  RESULTS
  It was possible to identify a subgroup of patients (representing 20% of total patients) with an 8-year survival of 75%. These patients were defined by the absence of t(4;14), del(17p), and 1q gain and β(2)-microglobulin less than 5.5 mg/L.
  
  
  CONCLUSIONS
  We propose that all patients with newly diagnosed multiple myeloma be evaluated for these three chromosomal changes, not only to define high-risk patients but also to identify those with a longer life expectancy.
authors.affiliation: Laboratoire d'Hématologie, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France. herve.avetloiseau@chu-nantes.fr
authors.forename: Hervé
authors.initials: H
authors.lastname: Avet-Loiseau
authors.forename: Michel
authors.initials: M
authors.lastname: Attal
authors.forename: Loic
authors.initials: L
authors.lastname: Campion
authors.forename: Denis
authors.initials: D
authors.lastname: Caillot
authors.forename: Cyrille
authors.initials: C
authors.lastname: Hulin
authors.forename: Gerald
authors.initials: G
authors.lastname: Marit
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Stoppa
authors.forename: Laurent
authors.initials: L
authors.lastname: Voillat
authors.forename: Marc
authors.initials: M
authors.lastname: Wetterwald
authors.forename: Brigitte
authors.initials: B
authors.lastname: Pegourie
authors.forename: Eric
authors.initials: E
authors.lastname: Voog
authors.forename: Mourad
authors.initials: M
authors.lastname: Tiab
authors.forename: Anne
authors.initials: A
authors.lastname: Banos
authors.forename: Jerome
authors.initials: J
authors.lastname: Jaubert
authors.forename: Didier
authors.initials: D
authors.lastname: Bouscary
authors.forename: Margaret
authors.initials: M
authors.lastname: Macro
authors.forename: Brigitte
authors.initials: B
authors.lastname: Kolb
authors.forename: Catherine
authors.initials: C
authors.lastname: Traulle
authors.forename: Claire
authors.initials: C
authors.lastname: Mathiot
authors.forename: Florence
authors.initials: F
authors.lastname: Magrangeas
authors.forename: Stephane
authors.initials: S
authors.lastname: Minvielle
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
mesh_terms: D000782:Aneuploidy; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002883:Chromosomes, Human, Pair 14; D002886:Chromosomes, Human, Pair 17; D002894:Chromosomes, Human, Pair 4; D018572:Disease-Free Survival; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000401:mortality*; D014178:Translocation, Genetic